Synthesis and evaluation of hybrid sulfonamide-chalcones with potential antileishmanial activity

Arch Pharm (Weinheim). 2024 Mar;357(3):e2300440. doi: 10.1002/ardp.202300440. Epub 2023 Dec 4.

Abstract

Leishmaniasis is an emerging tropical infectious disease caused by a protozoan parasite of the genus Leishmania. In this work, the molecular hybridization between a trimethoxy chalcone and a sulfonamide group was used to generate a series of sulfonamide-chalcones. A series of eight sulfonamide-chalcone hybrids were made with good yields (up to 95%). These sulfonamide-chalcones were tested against promastigotes of Leishmania amazonensis and cytotoxicity against mouse macrophages, which showed good antileishmanial activity with IC50 = 1.72-3.19 µM. Three of them (10c, 10g, and 10h) were also highly active against intracellular amastigotes and had a good selectivity index (SI > 9). Thus, those three compounds were docked in the cytosolic tryparedoxin peroxidase (cTXNPx) enzyme of the parasite, and molecular dynamics simulations were carried out. This enzyme was selected as a target protein for the sulfonamide-chalcones due to the fact of the anterior report, which identified a strong and stable interaction between the chalcone NAT22 (6) and the cTXNPx. In addition, a prediction of the drug-likeness, and the pharmacokinetic profile of all compounds were made, demonstrating a good profile of those chalcones.

Keywords: Leishmania amazonensis; amastigote; molecular docking; molecular dynamics; promastigote.

MeSH terms

  • Animals
  • Antiprotozoal Agents* / pharmacology
  • Chalcone* / pharmacology
  • Chalcones* / pharmacology
  • Mice
  • Structure-Activity Relationship
  • Sulfanilamide
  • Sulfonamides / pharmacology

Substances

  • Chalcones
  • Chalcone
  • Antiprotozoal Agents
  • Sulfanilamide
  • Sulfonamides